Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer.
Dómine Gómez M, Csőszi T, Jaal J, Kudaba I, Nikolov K, Radosavljevic D, Xiao J, Horton JK, Malik RK, Subramanian J. Dómine Gómez M, et al. Among authors: radosavljevic d. Int J Cancer. 2021 Oct 1;149(7):1463-1472. doi: 10.1002/ijc.33705. Epub 2021 Jul 10. Int J Cancer. 2021. PMID: 34109630 Free PMC article. Clinical Trial.
Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study.
Hart LL, Ferrarotto R, Andric ZG, Beck JT, Subramanian J, Radosavljevic DZ, Zaric B, Hanna WT, Aljumaily R, Owonikoko TK, Verhoeven D, Xiao J, Morris SR, Antal JM, Hussein MA. Hart LL, et al. Among authors: radosavljevic dz. Adv Ther. 2021 Jan;38(1):350-365. doi: 10.1007/s12325-020-01538-0. Epub 2020 Oct 29. Adv Ther. 2021. PMID: 33123968 Free PMC article. Clinical Trial.
Lung Cancer in Serbia.
Cavic M, Kovacevic T, Zaric B, Stojiljkovic D, Korda NJ, Rancic M, Jankovic R, Radosavljevic D, Stojanovic G, Spasic J. Cavic M, et al. Among authors: radosavljevic d. J Thorac Oncol. 2022 Jul;17(7):867-872. doi: 10.1016/j.jtho.2022.04.010. J Thorac Oncol. 2022. PMID: 35750454 Free article. No abstract available.
Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study.
Jelić S, Mitrović L, Radosavljević D, Elezar E, Babović N, Kovcin V, Tomasević Z, Kovacević S, Gavrilović D, Radulović S. Jelić S, et al. Among authors: radosavljevic d. Lung Cancer. 2001 Oct;34(1):1-13. doi: 10.1016/s0169-5002(01)00239-2. Lung Cancer. 2001. PMID: 11557107 Clinical Trial.
Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.
Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, Radosavljevic D, Paccagnella A, Zatloukal P, Mazzanti P, Bisset D, Rosell R; CISCA (CISplatin versus CArboplatin) Meta-analysis Group. Ardizzoni A, et al. Among authors: radosavljevic d. J Natl Cancer Inst. 2007 Jun 6;99(11):847-57. doi: 10.1093/jnci/djk196. J Natl Cancer Inst. 2007. PMID: 17551145
63 results